Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

MEDLINE INDUSTRIES, LP - Northfield

US Class II Ongoing · initiated 2025-07-07

Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

Anesketin 100 mg/mL solution for injection

Canada Type II Ongoing · initiated 2025-07-07

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

FDC Limited

US Class II Ongoing · initiated 2025-07-05

Defective Container: spike of the cap becomes lodged in the nozzle of the product bottle.

PMS-Methylphenidate CR 10 mg capsule

Canada Type I Ongoing · initiated 2025-07-04

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

RIVA-Fluoxetine 10 mg capsule

Canada Type I Ongoing · initiated 2025-07-03

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Lupin Pharmaceuticals Inc.

US Class II Completed · initiated 2025-07-02

Labeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027

Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles

US Class II Ongoing · initiated 2025-07-01

Lack of Processing Controls; prescriptions were compounded in an ISO-5 area where it was identified that a daily cleaning step was not sufficiently documented.

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-06-30

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Dr. Reddy's Laboratories, Inc.

US Class II Ongoing · initiated 2025-06-30

Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules.

Cipla USA, Inc.

US Class II Ongoing · initiated 2025-06-30

Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.

PMS-Fluoxetine 10 mg capsule

Canada Type I Ongoing · initiated 2025-06-30

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Dr. Nutrition 360 Magnesium 200 mg capsule

Canada Type III Ongoing · initiated 2025-06-30

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

PRO-Fluoxetine 10 mg capsule

Canada Type I Ongoing · initiated 2025-06-30

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Yi Li Xiao Capsule

Canada Type I Ongoing · initiated 2025-06-30

Product quality. Stop using Virility for Men (Yi Li Xiao Capsule).Consult your health care professional if you have used this product and have health concerns.R…

Sandoz Inc

US Class I Ongoing · initiated 2025-06-27

Labeling: Label Mix-Up; cartons of Cefazolin for Injection, USP 1 gram were found to contain vials labeled as penicillin G potassium for Injection, USP, 20 mill…

Sandoz Inc

US Class I Ongoing · initiated 2025-06-27

Labeling: Label Mix-Up; Some vials of Cefazolin for Injection, USP 1 gram were incorrectly labeled as penicillin G potassium for Injection, USP, 20 million Unit

Lupin Pharmaceuticals Inc.

US Class II Terminated · initiated 2025-06-27

Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during r…

AvKARE

US Class III Ongoing · initiated 2025-06-26

Failed Impurity/Degradation Specifications

AvKARE

US Class III Ongoing · initiated 2025-06-26

Failed Impurity/Degradation Specifications

Granules Pharmaceuticals Inc.

US Class II Ongoing · initiated 2025-06-24

Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.

Lupin Pharmaceuticals Inc.

US Class II Ongoing · initiated 2025-06-20

Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg h…

ACCORD HEALTHCARE, INC.

US Class II Ongoing · initiated 2025-06-20

Subpotent Drug: Assay below the approved specification

ACCORD HEALTHCARE, INC.

US Class II Ongoing · initiated 2025-06-20

Subpotent Drug: Assay below the approved specification

ACCORD HEALTHCARE, INC.

US Class II Ongoing · initiated 2025-06-20

Subpotent Drug: Assay below the approved specification

ACCORD HEALTHCARE, INC.

US Class II Ongoing · initiated 2025-06-20

Subpotent Drug: Assay below the approved specification